Although treatment of HER2-positive tumors with RT and an ICI remains uncommon, RT combined with anti-CTLA-4 and anti-HER2 mAbs increased the disease control rate after 12 weeks in patients with HER2-positive breast cancer and brain metastases [20]. The gene discussed is ERBB2; the disease is breast carcinoma.